Spin-off business OxiDx founded to unlock value from ‘2-tag’ measure for oxidative stress.
Oxidative stress has been implicated in many chronic diseases, and the ‘2-tag’ method could be part of the next generation of medical diagnostic tests. The technology has a number of target applications, including chronic fatigue, muscular dystrophy, high-performance athletes and the horse racing industry.
Stand-alone entity will focus on patented technology developed by Proteomics International and The University of Western Australia. Proteomics International and its shareholders will own 66 per cent of OxiDx, and The University of Western Australia will own 33 per cent.